Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Model-Guided Dose Adjustment of Sitagliptin and Duloxetine in Cirrhotic Diabetic Patients
NCT07439536Phase 4Completed
- Sponsor
- Kafrelsheikh University
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sitagliptin and duloxetine in type 2 diabetes mellitus (T2DM) and diabetic neuropathy (6 arms), sponsored by Kafrelsheikh University. Primary endpoint: Management of diabetes mellitus and diabetic neuropathy at 3 months. Started Jul 2024; status: completed.
02
Drugs
sitagliptinduloxetine
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic neuropathy
Beyond the preview
Go deeper on NCT07439536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439536.